Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wellcome Trust Launches £200 million “Evergreen” Investment Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

Britain’s charitable foundation The Wellcome Trust has formally launched a £200 million ($325 million) fund that will invest in both early and growth-stage companies, taking a long-term view and focused initially on opportunities in the UK, Europe and on the U.S East Coast.

You may also be interested in...

A Supercharged Charitable Investment Fund To Nurture UK's Biotech Ecosystem

The UK’s largest medical charities, the Wellcome Trust and Cancer Research UK, have backed the formation of a bulked-up £1bn long-term investment fund from the bringing together of Syncona, the CRT Pioneer Fund and BACIT, with the aim of building a self-sustaining UK biotech ecosystem.

Wellcome Trust’s Syncona Bets On Gene Therapy in Eye Disease

The profit-oriented evergreen fund of Britain’s charitable foundation The Wellcome Trust, Syncona, has invested £12 million in an academic spin-out to develop and commercialize therapies for treating degenerative eye diseases.

Wellcome Trust Launches £200 Million Fund For Diverse Health Care Investments

The U.K.’s largest charitable foundation for biomedical research is the sole investor in a new fund that will target start-ups as well as later-stage growth opportunities across the health care spectrum.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts